Bladder-sparing chemo-radiation plus immunotherapy for bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether adding immunotherapy drugs (nivolumab alone or nivolumab plus ipilimumab) to standard chemo-radiation can control muscle-invasive bladder cancer while helping people keep their bladder. It aims to find a safer, effective curative treatment for people who want to avoid bladder removal (cystectomy).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and can sign consent in writing
- You want to keep your bladder or you cannot safely have bladder removal surgery
- Your bladder tumor was checked with a biopsy and removed as much as safely possible within 35 days before treatment starts
- Your cancer is muscle-invasive bladder cancer (T2 to T4a) and has not spread to distant organs
- A scan within 28 days must show no distant spread (a few pelvic lymph nodes may be allowed)
- Your body can handle treatment based on recent lab tests, and you can attend frequent follow-up visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies giving toripalimab (an immunotherapy) together with gemcitabine and cisplatin before bladder surgery. It aims to shrink locally advanced bladder cancer and make surgery more effective by using the immune system and chemotherapy together.
This Phase 2 study tests giving standard chemotherapy first, then immunotherapy, followed by major surgery to remove the bladder/urinary tumor and nearby lymph nodes. It’s for people with locally advanced urothelial cancer whose cancer has at least not worsened after initial chemotherapy.
This Phase 2 study tests whether adding chemotherapy and immunotherapy along with targeted pelvic radiation after bladder tumor surgery can reduce bladder cancer returning or spreading. It focuses on people with non-metastatic, muscle-invasive urothelial bladder cancer.
This study tests a combination of chemotherapy, immunotherapy, and radiation to treat muscle-invasive bladder cancer while trying to avoid bladder removal. It compares this approach to a watch-and-wait strategy, and also looks at adding maintenance immunotherapy.
This trial tests adding two immunotherapy drugs (cemiplimab and fianlimab) to standard chemotherapy (gemcitabine and cisplatin) for people with bladder cancer that has grown into the muscle layer but hasn't spread. The goal is to see if adding these immunotherapies helps shrink the tumor before surgery.
This trial tests adding the drug Nimotuzumab to standard chemoradiation for people with muscle-invasive bladder cancer who cannot have or do not want surgery to remove the bladder. The goal is to see if this combination helps control the cancer while keeping the bladder.
Hear when a new Urinary Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.